Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDR1 | Q08345 | 9/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 6/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30393345 | 0.89 | EPHX2 (0.49) | EPHX2HDAC1HDAC6LMNAMAPK1 | |
| SCHEMBL25848879 | 0.89 | EPHX2 (0.49) | EPHX2HDAC1HDAC6LMNAMAPK1 | |
| SCHEMBL25848768 | 0.88 | KMT2A (0.39) | HDAC1HDAC6NPC1RAB9ALMNA | |
| SCHEMBL24196134 | 0.88 | P2RX7 (0.43) | DDR1EPHX2HDAC1HDAC6 | |
| SCHEMBL25848904 | 0.88 | EPHX2 (0.41) | DDR1EPHX2HDAC1HDAC6LMNA | |
| SCHEMBL25848887 | 0.87 | EPHX2 (0.45) | DDR1EPHX2HDAC1HDAC6MAPK1 | |
| SCHEMBL25848885 | 0.85 | DDR1 (0.45) | DDR1EPHX2HDAC1HDAC6 | |
| SCHEMBL24196676 | 0.85 | NLRP3 (0.43) | DDR1 | |
| SCHEMBL25848893 | 0.83 | EPHX2 (0.42) | DDR1EPHX2 | |
| SCHEMBL25848884 | 0.81 | CCR1 (0.47) | HDAC1HDAC6NPC1RAB9ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219921-A1 | KCNT1 INHIBITORS AND METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. | 2023-07-13 | — | — | US | disclosed |
| US-20230219921-A1 | KCNT1 INHIBITORS AND METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. | 2023-07-13 | — | — | US | disclosed |
| EP-4175624-A1 | KCNT1 INHIBITORS AND METHODS OF USE | Praxis Precision Medicines, Inc. (US) | 2023-05-10 | — | — | EP | disclosed |
| CN-116075297-A | KCNT1 inhibitors and methods of use | 普拉西斯精密医药公司 | 2023-05-05 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219921-A1 | KCNT1 INHIBITORS AND METHODS OF USE | KCNT1, KCNT2, KCNQ2 | DDR1 3524/4885EPHX2 2590/4885HDAC1 1680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.